Latest filing published 14 Jan 2026 for Olema Pharmaceuticals, Inc., €244k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
David C. Myles, listed as senior executive, appears in our data through filings on Olema Pharmaceuticals, Inc. shares, published by SEC (Form 4). The record holds 8 filings, for trades running from 10 December 2021 to 12 January 2026.
Sales make up the whole of the open-market record (6 sales, €700k). Besides market trades, the filings include 2 share grants. In 2026 alone, the filings show no purchases and 1 sale.
Most recently, on 14 January 2026, the filings show an open-market sale worth €244k in Olema Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations